Choongwae Enters Competitive Hyperlipidemia Treatment Market

Choongwae Pharmaceutical enters the domestic hyperlipidemia treatment market valued over 100 billion won by obtaining the market approval for Livalo, an original drug co-developed by Japan's Kowa Yakuhin and Nissan Chemical Industries.

Launched in Japan in September 2003, Livalo (active ingredient: pitavastatin) is regarded as a novel statin treatment, where its efficacy and safety profiles ...